While its biomedical innovation has demonstrated vigorous momentum in recent years, China is providing better and more affordable therapeutic solutions to meet global needs, Eric Tse, CEO of Sino Biopharm, said in a recent interview with China Global Television Network (CGTN) on the sidelines of the ongoing annual meeting of the World Economic Forum (WEF) in Davos, Switzerland.
He emphasized that China is emerging as a key player in global biopharmaceutical innovation.
"I think China has definitely taken a much bigger part of the role in terms of global innovation development. We can see that China's data really rise from 5 percent of having innovative [products] into past 50 percent. Last year, I think the deals right now are rising from the top 10 out-licensing deals raised from in the past, maybe zero number right now, it's like half of them around Chinese companies. I think this really came out from how our talent dividends really drove our innovation going forward. And then, I think in the future, in the coming years, there will be more and more China-developed assets -- or not only fast-follower drugs but innovative drugs and products, that will be going forward. We're anticipating a very good 2026 or even 2027," said Eric Tse.
He further underscored that China's world-class biopharma clusters are driving medical innovations that benefit patients across the globe.
"China assets can really benefit the world. It's not only in the drug or the asset itself, but also on the infrastructure and ecosystem that it's building. Right now, it's like Shanghai, Beijing, Guangzhou, and let's say Jiangsu has a lot of cluster in terms of biotech pharmaceuticals. And, it is a, I think, given more and more attention in comparison in a decade ago -- a decade ago again, maybe you only have 5 percent of innovation globally. Right now, it's like that number went up by, let's say, at least four or five times. So, I think this is how we contribute to global med-needs and therapies, and having patients to access faster and better and more affordable therapies," he said.
Under the theme "A Spirit of Dialogue," the five-day 2026 WEF annual meeting is running in Davos through Friday. About 3,000 leaders and experts from around the world are gathering to discuss five pressing global challenges, including enhancing cooperation, unlocking new sources of growth and deploying innovation at scale and responsibly.
China's biotech clusters fuel better, affordable therapies for worldwide needs: insider
China's biotech clusters fuel better, affordable therapies for worldwide needs: insider
